| Title |
The histone deacetylase inhibitor BML-210 influences on gene and protein expression in human promyelocytic leukemia NB4 cells via epigenetic reprogramming / |
| Authors |
Borutinskaitė, Veronika Viktorija ; Navakauskienė, Rūta |
| DOI |
10.3390/ijms160818252 |
| Full Text |
|
| Is Part of |
International journal of molecular sciences.. Basel : MDPI AG. 2015, vol. 16, iss. 8, p. 18252-18269.. ISSN 1422-0067 |
| Keywords [eng] |
Leukemia ; HDAC ; BML-210 ; ATRA ; Granulocytic differentiation |
| Abstract [eng] |
Background: Today, cancer is understood as an epigenetic as well as genetic disease. The main epigenetic hallmarks of the cancer cell are DNA methylation and histone modifications. Proteins such as histone deacetylases (HDACs) that cause modifications of histones and other proteins can be targets for novel anticancer agents. Recently interest in compounds that can inhibit HDACs increased and now there are so many HDACIs available with different chemical structures, biological and biochemical properties that hopefully some of them will succeed, probably in combination with other agents, in cancer therapies. Results: In our study we focused ourselves on a novel HDACI – BML-210. We found that BML-210 inhibits the growth of NB4 cells in dose and time-dependent manner. In this study we also examined how expression and activity of HDACs are affected after leukemia cell treatment with BML-210. Using mass spectrometry method we identified proteins that changed expression after treatment with BML-210. We prepared RT-PCR analysis of these genes and results correlated with proteomic data. Conclusion: Based on these and other our group finding, we suggest that HDACIs, like BML-210, can be promising anticancer agents in promyelocytic leukemia treatment. |
| Published |
Basel : MDPI AG |
| Type |
Journal article |
| Language |
English |
| Publication date |
2015 |
| CC license |
|
